Relative Adrenocortical Insufficiency Following Radioactive Iodine Therapy for Graves' Disease: A Report of Two Cases

Hanxin Zhao

Yu Ruan

Department of Endocrinology and Metabolism, Zhejiang University Affiliated Sir Run Run Shaw Hospital, School of Medicine, Hangzhou, People's Republic of China

Introduction: In recent years, radioactive iodine (RAI) therapy has become a main choice for Graves' disease. The rapid release of thyroid hormones following RAI may on occasion trigger severe events, such as thyroid storm or heart block. This study presents two cases of possible acute adrenocortical insufficiency precipitated by radioiodine therapy.

Case Presentation: Two females aged 65 and 19 years with long-standing Graves' disease underwent radioiodine treatment at our clinical center. Both patients suffered nausea, fatigue, aggravated palpitation, and relative hypotension thereafter. Laboratory data showed severe thyrotoxicosis with free thyroxine higher than three times the upper limit, while basal serum cortisol (8 AM) was below the lower limit (5.08 µg/dL and 2.08 µg/dL respectively) under stress, indicating a potential relative adrenocortical insufficiency. There was then full recovery after adequate hydrocortisone therapy. As thyrotoxicosis resolved, the levels of basal cortisol were subsequently raised to normal.

Conclusion: Post-RAI adrenocortical insufficiency might occur in patients with severe Graves' disease. Basal serum cortisol might be a cost-effective parameter for the identification of potential patients.

Keywords: Graves' disease, hyperthyroidism, adrenal insufficiency, radioiodine therapy

Introduction

China is a populous country with a high incidence of Graves' hyperthyroidism (1.1%–1.4%).¹ Nowadays, an increasing number of Chinese patients come to accept radioactive iodine (RAI) therapy,² which has been considered efficient and well tolerated for decades.³ As guidelines advised,³ physicians should fully communicate with patients about the benefits, expected speed of recovery, drawbacks, and potential side effects. Therefore, any unusual emergency that occurs at any point in time during medical practice deserve attention.

Previous studies have shown that thyroxine could enhance the clearance and synthetic rate of cortisol, with a balanced net effect most of the time.^{4,5} When people are in stress like rapidly worsened hyperthyroidism, or new onset thyrotoxicosis in patients with primary adrenocortical insufficiency, a latent adrenal crisis may emerge. Due to the low incidence and confusing manifestations, diagnosis might be delayed.^{6–8}

In this study, to highlight the masked threatening condition, we describe two cases of Graves' disease who developed relative adrenocortical insufficiency post-RAI therapy.

Correspondence: Yu Ruan
Department of Endocrinology and Metabolism, Zhejiang University Affiliated Sir Run Run Shaw Hospital, School of Medicine, 3 East Qingchun Road, Hangzhou, 310016, People's Republic of China
Tel +86 571 86006171
Email ruanyu2019@zju.edu.cn

Case Presentation

Case I

A 65-year-old woman with palpitation and weight loss presented to our hospital for RAI therapy. She was diagnosed to have Graves' disease one month previously. After taking methimazole (MMI) 10 mg for three weeks, she was found to have mild leukopenia (white-cell count 2940/mm³, 1730 neutrophils/mm³). She reported no fever, cough, diarrhea, stomachache, nausea, vomiting, or dizziness. The patient had received montelukast and cetirizine hydrochloride for chronic bronchitis. Her heart rate was 98 bpm and blood pressure 136/79 mmHg. On physical examination, the goiter was enlarged with no tenderness. The lung was clear and heart rate was regular, without a murmur. She was found to have an undetectable thyroid stimulating hormone (TSH) of 0.00 mIU/L (0.35–4.94 mIU/L) and an elevated free thyroxine (FT4) level of 1.62 ng/dL (0.7–1.48 ng/dL). Other parameters are shown in Table 1. An electrocardiogram (ECG) revealed sinus rhythm, a ventricular rate of 96 bpm. Echocardiography revealed normal left ventricular systolic function with an ejection fraction of 66%. A technetium-99m thyroid scintigraphy revealed diffusely elevated uptake in the goiter and a thyroid weight of 81.97 g. RAI uptake test demonstrated 62.8% uptake in 24 h. Due to her concern over the side effects of anti-thyroid drugs (ATD), the patient chose RAI treatment. After the correction of leucopenia, she received ¹³¹I administration of 10 mCi in March 2017, and was discharged on metoprolol.

Two weeks later, the patient returned to the emergency department presenting with appetite loss, nausea, vomiting,

fatigue, edema, and aggravated palpitation. Upon arrival, she had sinus tachycardia (113 bpm), relative hypotension (92/60 mmHg), with a normal temperature. Physical examination revealed emaciation, dysphoria, diaphoresis, diffuse non-tender thyromegaly (Grade II), and mild pitting edema of the eyelids and lower extremities. The lung was clear, her abdomen was not tender, and murphy's sign was negative. Thyroid function showed exacerbated thyrotoxicosis: TSH 0.00 mIU/L, FT4 4.48 ng/dL, free triiodothyronine (FT3) >30.00 pg/mL (1.71–3.71 pg/mL), thyrotrophin receptor antibody (TR-Ab) 37.47 IU/L (0.00–1.22 IU/L). The white-cell count was 4500/mm³, and neutrophils 2800/mm³. The sodium level was 137 mmol/L, potassium level 4.0 mmol/L, chloride level 104 mmol/L, and fasting blood glucose was 4.77 mmol/L. The levels of plasma troponin, NT-proBNP, serum hepatic enzymes, bilirubin, and creatinine were all within the reference range.

Given that the patient developed symptoms in a short time after radioactive therapy, thyroid storm was the first probable diagnosis. However, she had no fever, no signs of central nervous system disturbance, infection, or heart failure. According to the Burch-Wartofsky Point Scale or Japanese Thyroid Association criteria,⁹ neither early stage or suspected thyroid storm were supported. Given her weakness, appetite loss, gastrointestinal symptoms, hypotension, and low-normal serum sodium, adrenocortical insufficiency had to be excluded. Laboratory data revealed decreased basal serum cortisol (5.08 µg/dL) and elevated plasma adrenocorticotrophic hormone (ACTH) (112 ng/L) under such stress. Her sexual hormone profile revealed a normal post-menopausal state. Abdominal and adrenal

Table 1 Thyroid Function Profile and Serum Cortisol Level in Case I

Time After RAI	Day of RAI	2 Weeks	2 Months	3 Months	6 Months	Reference
TSH (mIU/L)	0	0	0	0	0	0.35–4.94
TT3 (ng/mL)	1.76	>8.00	2.42	2.04	1.48	0.58–1.59
TT4 (µg/dL)	9.9	21.05	12.87	6.79	5.05	4.87–11.72
FT3 (pg/mL)	5.95	>30.0	NA	6.76	4.31	1.71–3.71
FT4 (ng/dL)	1.62	4.48	NA	1.36	0.86	0.7–1.48
TR-Ab (IU/L)	6.33	37.47	>40.0	>40.0	>40.0	0.00–1.22
Basal Cortisol (8AM, µg/dL)	NA	5.08	9.95	8.08	10.5	6.70–22.6

Note: Thyroid function profiles were measured by chemiluminescence microparticle immuno assay and serum cortisol was measured by chemiluminescence immunoassay. **Abbreviations:** TSH, thyroid stimulating hormone; TT3, total triiodothyronine; TT4, total thyroxine; FT3, free triiodothyronine; FT4, free thyroxine; TR-Ab, thyrotrophin receptor antibody; NA, not available.

ultrasound findings were unremarkable. Since the patient had no history or presentation of pituitary or adrenal disorders, and she had no history of exposure to exogenous glucocorticoid, a diagnosis of acute adrenocortical insufficiency following RAI therapy was highly suspected.

Subsequently, 100 mg hydrocortisone succinate was given intravenously followed by appropriate fluid resuscitation. Her symptoms diminished soon and her blood pressure was normalized (130/74 mmHg). She was then placed on tapered hydrocortisone and propylthiouracil (PTU). On the day of discharge, she was prescribed 20 mg hydrocortisone and 100 mg PTU daily. At two months follow-up, the patient stated that she had no discomfort and discontinued hydrocortisone by herself one week prior. Labs at that time showed normalized levels of basal cortisol (9.95 µg/dL) and serum electrolytes (sodium level 142 mmol/L, potassium level 4.1 mmol/L). PTU was then reduced to 50 mg daily based on thyroid function. It remained stable during the subsequent follow-up visits. The relation of her FT4, FT3, and cortisol levels over time is demonstrated graphically in Figure 1.

Case 2

A 19-year-old female was admitted to our department for RAI therapy in July 2018 due to her 10-year recurrent Graves' hyperthyroidism. She had a parental family history of Graves' disease. She was on 10 mg propranolol three times a day and MMI 10 mg once daily. Her heart rate was 113 bpm and blood pressure was 124/74 mmHg. On physical examination, the goiter was visibly enlarged with a murmur, no edema, pigmentation or hair loss. Her heart rate was regular, and an ECG revealed sinus tachycardia (110 bpm) and a prolonged corrected QT interval. Blood tests indicated severe hyperthyroidism (TSH 0.00 mIU/L; FT4 4.41 ng/dL; FT3 >30.00 pg/mL; TR-Ab >40.0 IU/L). A technetium-99m thyroid scintigraphy revealed

diffusely elevated uptake in the goiter and a thyroid weight of 210.04 g. RAI uptake test showed a homogenous gland with 69.4% uptake in 2 h and 65.5% in 24 h. MMI was discontinued three days prior to ¹³¹I administration. A dose of 12 mCi radioiodine was administered orally and propranolol was prescribed 10 mg every six hours.

Three days after ¹³¹I administration, she developed appetite loss, vomiting, fatigue, headache, and aggravated palpitation. When she presented to our hospital the day after symptom onset, her temperature was 36.9°C, heart rate was 122 bpm and blood pressure was 105/65 mmHg. On physical examination, the goiter was visibly enlarged and non-tender. Abdominal and neurological examinations were unremarkable. The levels of FT4 and FT3 were higher than the upper limit (details in Table 2). The sodium level was 133 mmol/L, potassium level 4.33 mmol/L, and chloride level 102 mmol/L. The high-sensitivity C-reactive protein, erythrocyte sedimentation rate, hepatic enzyme spectrum, and renal function were all within normal range. Random serum cortisol was 2.08 µg/dL under such stress. Craniocerebral and abdominal CT scan was unrevealing.

Similarly, combined with her history and testing results, a probable diagnosis of acute adrenocortical insufficiency was considered. In the emergency room, 50 mg hydrocortisone succinate was given intravenously, which provided immediate relief. She was discharged later on hydrocortisone orally for three days.

One month later, she returned to the clinic without discomfort. Her basal serum cortisol level was raised to normal (cortisol 11.14 µg/dL). The levels of FT4, TT4, FT3, and TT3 were still higher than the upper limit. She resumed taking MMI 20 mg daily and the dose varied depending on thyroid function. One year later, the patient received a second dose of ¹³¹I administration (10 mCi) under close observation. This time, she reported no fever, no appetite loss, no nausea, or headache and had a normal level of basal serum cortisol (8.79 µg/dL) after RAI therapy.

Discussion

The cooperative effects of thyroxine and glucocorticoids have been well documented. In clinical practice, adrenocortical insufficiency, a potentially life-threatening syndrome may occur when thyrotoxicosis is exacerbated. It has been reported in situations such as misuse of thyroid hormone in a background of latent adrenal insufficiency,^{10,11} new onset thyrotoxicosis in a patient with congenital adrenal

Figure 1 Graphic demonstration of FT4, FT3, and cortisol levels over time in case 1.

Table 2 Changes of Thyroid Function and Serum Cortisol in Case 2

Time After RAI	Day of RAI	3 Days	1 Month	12 Months*	14 Months	28 Months	Reference
TSH (mIU/L)	0	0	0	0	0.59	0	0.35–4.94
TT3 (ng/mL)	>8.00	>8.00	>8.00	>8.00	0.39	1.15	0.58–1.59
TT4 (μg/dL)	22.84	>24.0	>24.0	>24.0	2.06	7.52	4.87–11.72
FT3 (pg/mL)	>30.0	>30.0	>30.0	>30.0	1.17	3.66	1.71–3.71
FT4 (ng/dL)	4.41	>5.0	>5.0	4.7	0.47	1.22	0.7–1.48
TR-Ab (IU/L)	>40.0	>40.0	>40.0	>40.0	>40.0	38.96	0.00–1.22
Basal Cortisol (8AM, μg/dL)	NA	2.08	11.14	8.79	NA	NA	6.70–22.6

Note: *The day around the second ^{131}I administration.

Abbreviations: TSH, thyroid stimulating hormone; TT3, total triiodothyronine; TT4, total thyroxine; FT3, free triiodothyronine; FT4, free thyronine; TR-Ab, thyrotrophin receptor antibody; NA, not available.

hyperplasia,⁶ or secondary adrenal insufficiency,⁸ and simultaneous presentation of Graves' disease and Addison's disease.⁷

Previous research demonstrated the association between long-standing thyrotoxicosis and deficient adrenocortical reserves,^{12–16} despite the lasting hyperactivity of the hypothalamic-pituitary-adrenal axis.¹⁷ In drug-induced hyperthyroid rat models, plasma corticosterone could be effectively increased in response to ACTH release.¹⁵ Similarly, in humans, due to the elevated metabolic rates, severe thyrotoxicosis may lead to adrenocortical insufficiency, which presents as significant hypocortisolemia or inadequate cortisol response to ACTH stimulation.^{12–14} Although it often occurs in a subclinical state and would resolve after the attainment of euthyroidism, patients are at increased risks of adrenal crisis^{10,17,18} when in stress of diarrhea, infection, surgery, or experiencing a sharp release of thyroid hormones. Conversely, evidence has shown that Graves' disease shares a similar process with other autoimmune endocrine diseases like autoimmune thyroiditis, thyroid eye disease, Type 1 diabetes and Addison's disease through cytokines.^{19,20} Hence, adrenal insufficiency might be a result of immune response to Graves' thyrotoxicosis under certain stimuli.

For Graves' thyrotoxicosis, RAI treatment, ATD, and thyroidectomy are main modality therapies. Despite the regional preferences, RAI has become more popular given its safety and efficiency.²¹ According to the American thyroid Association Guideline for Hyperthyroidism in 2006,³

59.7% of respondent clinical endocrinologists from the United States selected RAI as primary choice, compared to 32% among Chinese physicians.² During previous clinical practice, much attention has been given to radiation thyroiditis, which is caused by a transient exacerbation of hyperthyroidism.²² Actually, factors like inaccurate dose due to potential changes of pre- to intra-therapeutically biokinetics of ^{131}I may induce side effects such as thyroid swelling, sialadenitis, or immune response.^{23–25} RAI therapy may even trigger rare complications like thyroid storm and heart block.²⁶

Combined with the aforementioned points, one may reasonably conceive that some patients would suffer symptoms of cortisol deficiency in the post-RAI period due to the short-term worsening of hyperthyroidism or the possible immune interaction. As far as is known, there is yet no such report of a clinical study or observation.

In the current study, we report two cases with Graves' thyrotoxicosis that manifested similarly with loss of appetite, fatigue, and aggravated palpitation in a short time after radioactive therapy, in whom the diagnosis was presumed to be radiation thyroiditis or the early stage of thyroid storm. However, further tests revealed low AM serum cortisol in the face of stress, indicating a likely underlying acute adrenocortical insufficiency, or even concomitant with thyroid storm. At the initial presentation of case 1, given the test result of high ACTH and hypocortisolemia, we were not sure whether she had prior primary adrenal insufficiency or not. Then through close follow-up, we discovered that

the patient no longer needed glucocorticoid replacement and achieved normalized cortisol and ACTH as FT3, FT4 trended down, which confirmed our suspicion that this was a transient adrenocortical insufficiency.²⁷ On this base, we started to evaluate adrenocortical function for patients with severe thyrotoxicosis after ¹³¹I administration. Most patients had normal basal cortisol except the second case. The girl had a 10-year course of Graves' disease, with an extremely high level of FT3, FT4, and elevated uptake of technetium-99m. Within a short time after RAI therapy, she soon exhibited classic presentations of acute adrenocortical insufficiency with hypocortisolism. After timely supplement of hydrocortisone her symptoms diminished rapidly and she finally attained normalized cortisol level as FT3, FT4 went down. However, there were several limitations to the present study that warrant discussion. First, none of the patients accepted adrenal stimulation testing during convalescence due to personal reasons. An entire evaluation would provide results that are more reliable. Second, cortisol-binding globin was not available in our center, which was a possible confounder as it might be low in patients with thyrotoxicosis.¹⁶ Third, the intra-therapeutic ¹³¹I uptake and effective half-life (EHL) for patients were not evaluated, which may influence therapeutic outcome or trigger potential side effects.^{23,24}

In summary, based on these two cases, we propose that the adrenocortical function of patients with severe thyrotoxicosis be evaluated around ¹³¹I administration for. Determination of the basal serum cortisol level is an optional screening test in testing-limited institutions. For hemodynamically stable patients, high-dosage (250 µg) ACTH stimulation test is advised. Adrenocortical insufficiency is conclusive when serum cortisol concentration cannot reach 18 µg/dL within 60 min.²⁸ Moreover, prophylactic glucocorticoid could be considered around the day of ¹³¹I administration in critical patients with free thyroxine 2–3 times the upper limit of the normal.²⁹ Methylprednisolone may be preferred to prednisolone to obtain a stable intra-therapeutic EHL of ¹³¹I.²³ If suspected adrenal crisis does occur following RAI, we suggest performing random serum cortisol and plasma ACTH measurement immediately and giving intravenous hydrocortisone succinate and fluid resuscitation. The dose and course depend on individual varied conditions.

Conclusion

Although RAI therapy has been widely used and well tolerated for decades,³ it should be treated with caution for those with prolonged severe Graves' disease, as they may face an increased risk of relative adrenal insufficiency. Basal or stimulated cortisol might be evaluated around ¹³¹I administration if available. Pretreatment with adequate glucocorticoid in necessity might be beneficial.

Ethics and Consent Statement

This study was performed in accordance with the principles of the Helsinki Declaration and approved by the Ethics Committee of Zhejiang University, School of Medicine affiliated Sir Run Run Shaw Hospital.

Consent for Publication

Written informed consents for publication were obtained from our patients.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Disclosure

The authors declare that there are no conflicts of interest.

References

1. Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China. *N Engl J Med*. 2006;354(26):2783–2793. doi:10.1056/NEJMoa054022
2. Ningyi J, et al. Guidelines for radioactive iodine therapy for graves' hyperthyroidism. *Chin J Endocrinol Metabol*. 2013;29(6):448–459.
3. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. *Thyroid*. 2016;26(10):1343–1421. doi:10.1089/thy.2016.0229
4. Hoshiro M, Ohno Y, Masaki H, et al. Comprehensive study of urinary cortisol metabolites in hyperthyroid and hypothyroid patients. *Clin Endocrinol (Oxf)*. 2006;64(1):37–45. doi:10.1111/j.1365-2265.2005.02412.x
5. Gallagher TF, Hellman L, Finkelstein J, et al. Hyperthyroidism and cortisol secretion in man. *J Clin Endocrinol Metabol*. 1972;34(6):919. doi:10.1210/jcem-34-6-919
6. Fredette ME, Topor LS. Graves' thyrotoxicosis leading to adrenal decompensation and hyperandrogenemia in a pediatric patient with salt-wasting congenital adrenal hyperplasia. *Case Rep Endocrinol*. 2018;2018:2359205.
7. Attaye I, van Anel M, Kooter AJ. More, less or both? *BMJ Case Rep*. 2018;2018. doi:10.1136/bcr-2017-222355
8. Skamagas M, Geer E. Autoimmune hyperthyroidism due to secondary adrenal insufficiency: resolution with glucocorticoids. *Endocrine Pract*. 2011;17(1):85–90. doi:10.4158/EP10069.CR

9. Satoh T, Iozaki O, Suzuki A, et al. 2016 guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition). *Endocr J*. 2016;63(12):1025–1064. doi:10.1507/endocrj.EJ16-0336
10. Naik D, Jebasingh KF, Thomas N. Delayed diagnosis of Graves' thyrotoxicosis presenting as recurrent adrenal crisis in primary adrenal insufficiency. *J Clin Diagn Res*. 2016;10(4):OD20–2. doi:10.7860/JCDR/2016/16395.7678
11. Bernet VJ. Thyroid hormone misuse and abuse. *Endocrine*. 2019;66(1):79–86. doi:10.1007/s12020-019-02045-1
12. Karl M, Onumah BM, Cole J, et al. Hypocortisolemia in Graves hyperthyroidism. *Endocrine Pract off J Am College Endocrinol Am Assoc Clin Endocrinol*. 2009;15(3):220. doi:10.4158/EP.15.3.220
13. Agbaht K, Gullu S. Adrenocortical reserves in hyperthyroidism. *Endocrine*. 2014;45(1):136–143. doi:10.1007/s12020-013-9933-y
14. Price SA, Thondam S, Bondugulapati LNR, et al. Significant attenuation of stimulated cortisol in early Graves disease without adrenal autoimmunity. *Endocrine Pract off J Am College Endocrinol Am Assoc Clin Endocrinol*. 2012;18(6):924. doi:10.4158/EP.12002.OR
15. Johnson EO, Kamilaris TC, Calogero AE, et al. Experimentally-induced hyperthyroidism is associated with activation of the rat hypothalamic–pituitary–adrenal axis. *Eur J Endocrinol*. 2005;153(1):177–185. doi:10.1530/eje.1.01923
16. Mishra SK, Gupta N, Goswami R. Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 microg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: case-control comparative study. *J Clin Endocrinol Metab*. 2007;92(5):1693–1696. doi:10.1210/jc.2006-2090
17. Tsatsoulis A, Johnson EO, Kalogera CH, et al. The effect of thyrotoxicosis on adrenocortical reserve. *Eur J Endocrinol*. 2000;142(3):231. doi:10.1530/eje.0.1420231
18. Satoh M, Aso K, Ikehara S, et al. A 3-year-old girl with Graves' disease with hypoglycemia following transient adrenal hyporesponsiveness. *J Pediatr Endocrinol Metab*. 2011;24(11–12):1047–1050. doi:10.1515/JPEM.2011.307
19. Fallahi P, Ferrari SM, Ragusa F, et al. Th1 chemokines in autoimmune endocrine disorders. *J Clin Endocrinol Metab*. 2020;105(4):1046–1060. doi:10.1210/clinem/dgz289
20. Weetman A. Autoimmune thyroid disease. *Endocrine*. 2020;68(2):258–260. doi:10.1007/s12020-020-02188-6
21. Kim M, Kim BH, Jang MH, et al. High neutrophil-to-lymphocyte ratio is associated with relapse in Graves' disease after antithyroid drug therapy. *Endocrine*. 2020;67(2):406–411. doi:10.1007/s12020-019-02137-y
22. Mizokami T, Hamada K, Maruta T, et al. Painful radiation thyroiditis after ¹³¹I therapy for graves' hyperthyroidism: clinical features and ultrasonographic findings in five cases. *Eur Thyroid J*. 2016;5(3):201–206. doi:10.1159/000448398
23. Happel C, Kranert WT, Gröner D, et al. Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of ¹³¹I during radioiodine therapy of Graves' disease. *Endocrine*. 2021. doi:10.1007/s12020-020-02593-x
24. Halstenberg J, Kranert WT, Korkusuz H, et al. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of ¹³¹I radioiodine therapy in Graves' disease]. *Nuklearmedizin*. 2018;57(2):43–49. German. doi:10.3413/Nukmed-0941-17-11
25. Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. *Endocr Rev*. 2012;33(6):920–980.
26. Vennard K, Gilbert MP. Thyroid storm and complete heart block after treatment with radioactive iodine. *Case Rep Endocrinol*. 2018;2018:8214169. doi:10.1155/2018/8214169
27. Nascif SO, Molica P, Correa-Silva SR, et al. Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis. *Pituitary*. 2009;12(4):315–321. doi:10.1007/s11102-009-0181-3
28. Annane D, Pastores SM, Rochwerf B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. *Intensive Care Med*. 2017;43(12):1751–1763. doi:10.1007/s00134-017-4919-5
29. Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. *Eur Thyroid J*. 2016;5(1):9–26. doi:10.1159/000443828

International Journal of General Medicine

Dovepress

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies

across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>